• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Uveitis Market 2014-2018 - Product Image

Global Uveitis Market 2014-2018

  • Published: May 2014
  • Region: Global
  • 73 pages
  • TechNavio
Promising Uveitis Treatment Pipeline Paving the Way for Market Growth


  • Abbvie Inc.
  • Alcon Laboratories Inc.
  • Allergan Inc.
  • Bausch & Lomb Inc.
  • Enzo Biochem Inc.
  • Lux Biosciences Inc.
  • MORE

About Uveitis

Uveitis is defined as the inflammation of the middle layer of the eye i.e. the uvea, also known as the uceal tract. The uvea consists of the iris, choroid and ciliary body. Infections, injury and autoimmune disorders may be related with the development of uveitis; however, the exact cause is often unknown. Various types of uveitis are: anterior uveitis, intermediate uveitis, posterior uveitis, and pan uveitis. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis can be serious, leading to permanent vision loss.

The analysts forecast the Global Uveitis market will grow at a CAGR of 26.46 percent over the period 2013-2018.

Covered in this Report
The Global Uveitis market can be segmented into three divisions: the Americas, and the EMEA and APAC regions. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of uveitis.

The report, the Global Uveitis Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; READ MORE >

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Treatment Options for Uveitis
09. Pipeline Snapshot
10. Rate of Incidence and Prevalence
10.1.1 US
10.1.2 Europe
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors
20. Key Vendor Analysis
21. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Uveitis Market 2013-2018 (US$ billion)
Exhibit 3: Off-label Use of Biologic Drugs For the Treatment of Uveitis
Exhibit 4: Global Uveitis market by Geographical Segmentation

Commenting on the report, an analyst from the team said: “Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products namely Alcon Laboratories's Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert. The expected entry of new players such as Lux Biosciences's Luveniq (NDA filled), pSivida Corp.'s Medidur (phase III), and Santen Pharmaceutical Co. Ltd.'s DE-109 (phase III) within the forecast period is expected to intensify the competition in future. The products currently available in the market are associated with low safety and as those products do not serve the market's unmet need, the market continues to present opportunities for stronger pipeline candidates. ”

According to the report, one of the main drivers in this market is the increasing prevalence of eye disorders around the world, which has consequently led to a rise in the incidence of uveitis. Uveitis is responsible for approximately 5 to 20 percent of legal blindness in western countries and approximately 25 percent of blindness in the developing world. Since uveitis involves lifelong medication and constant physician supervision, the market can expect a rise in the patient population over the next few years.

Further, the report states that one of the main challenges is the unknown etiology of uveitis. The diverse etiology of uveitis continues to be a challenge for the market growth as diverse treatment options are required, and this presents a challenge for patient enrolment in clinical trials.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- Abbvie Inc.
- Alcon Laboratories Inc.
- Allergan Inc.
- Bausch & Lomb Inc.
- Artielle ImmunoTherapeutics Inc.
- Enzo Biochem Inc.
- Hanall Pharmaceutical Co. Ltd.
- Lux Biosciences Inc.
- OphthaliX Inc.
- Regeneron Pharmaceuticals Inc.
- TopiVertLtd.
- pSivida Corp.
- XOMA Corp.
- Santen Pharmaceutical Co.

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos